{
  "ticker": "MNPR",
  "company_name": "Monopar Therapeutics Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06337084",
      "title": "Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer",
      "start_date": "2024-05-30",
      "completion_date": "2026-04",
      "enrollment": 0,
      "sponsor": "Monopar Therapeutics"
    },
    {
      "nct_id": "NCT06617169",
      "title": "Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer",
      "start_date": "2024-10-08",
      "completion_date": "2027-01",
      "enrollment": 0,
      "sponsor": "Monopar Therapeutics"
    },
    {
      "nct_id": "NCT05043649",
      "title": "Camsirubicin + Pegfilgrastim to Determine MTD in ASTS",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Advanced Soft-tissue Sarcoma",
      "start_date": "2021-09-22",
      "completion_date": "2024-05-13",
      "enrollment": 0,
      "sponsor": "Monopar Therapeutics"
    },
    {
      "nct_id": "NCT06980519",
      "title": "MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Cancer, Solid Tumor, Solid Tumor Cancer, Oncology, uPAR-positive Solid Tumor, Urokinase Plasminogen Activator Receptor-positive Solid Tumor",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Monopar Therapeutics"
    },
    {
      "nct_id": "NCT04648020",
      "title": "Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.",
      "status": "TERMINATED",
      "phase": "PHASE2, PHASE3",
      "condition": "Chemoradiotherapy-Induced Severe Oral Mucositis",
      "start_date": "2021-02-11",
      "completion_date": "2023-05-14",
      "enrollment": 0,
      "sponsor": "Monopar Therapeutics"
    },
    {
      "nct_id": "NCT06980506",
      "title": "MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "Cancer, Solid Tumor, Solid Tumor, Adult",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Monopar Therapeutics"
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE1": 3,
      "": 2,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "RECRUITING": 2,
      "TERMINATED": 2,
      "AVAILABLE": 2
    },
    "active_trials": 2,
    "completed_trials": 0,
    "conditions": [
      "Advanced Soft-tissue Sarcoma",
      "Cancer, Solid Tumor, Solid Tumor Cancer, Oncology, uPAR-positive Solid Tumor, Urokinase Plasminogen Activator Receptor-positive Solid Tumor",
      "Cancer, Solid Tumor, Solid Tumor, Adult",
      "Chemoradiotherapy-Induced Severe Oral Mucositis",
      "Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:36:10.565969",
    "search_query": "Monopar Therapeutics Inc.",
    "url": "https://clinicaltrials.gov/search?term=Monopar+Therapeutics+Inc."
  }
}